Jin Urban Pharmaceutical: Subsidiary Jin Urban Heping obtains the registration certificate for Butorphanol Tartrate Injection.

Jin Medicine Industry announced that its subsidiary Jin Medicine He Ping has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the oxycodone tartrate injection. The drug belongs to the second category of psychoactive drugs and is indicated for the treatment of various cancer-related pain and postoperative pain. Jin Medicine He Ping has invested approximately 22 million yuan in research and development expenses for this project. According to data from Minet, the domestic sales of oxycodone tartrate injection in 2023 and 2024 are expected to reach 1.965 billion yuan and 1.899 billion yuan respectively. The approval of this drug will further enrich the company's product pipeline in the field of psychoactive drugs and have a positive impact on its business performance.